04.10.2016
Evotec AG DE0005664809
DGAP-News: EVOTEC AND CARRICK THERAPEUTICS BUILD STRATEGIC ALLIANCE
DGAP-News: Evotec AG / Key word(s): Alliance
EVOTEC AND CARRICK THERAPEUTICS BUILD STRATEGIC ALLIANCE
04.10.2016 / 07:29
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
- Evotec contributes $ 6 m to Carrick's $ 95 m funding round through a
top-class global investor consortium
- Carrick Therapeutics ("Carrick") and Evotec build discovery alliance for
novel oncology targets
Hamburg, Germany, 04 October 2016:
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809)
announced today that in line with its strategy to participate in promising
corporate formations it will deepen its already existing relationship with
Carrick. Evotec will invest up to $ 6 m towards Carrick's latest funding
round. The total $ 95 m round was led by ARCH Venture Partners and Woodford
Investment Management with participation from Cambridge Enterprise Seed
Funds, Cambridge Innovation Capital, Google Ventures (GV), Lightstone
Ventures, and Evotec AG.
Carrick, headquartered in Dublin with R&D located in Oxford and Dublin has
a clear vision for cancer patients: Its mission is to target the molecular
pathways that drive the most aggressive and resistant forms of cancer in
order to have a major impact on the lives of patients. Instead of banking
on a single compound or biological mechanism, Carrick is building an
innovative portfolio of first-in-class treatments that target multiple
mechanisms of the most aggressive forms of cancer, and which will be
tailored to an individual patient's tumour. To support this mission Evotec
will provide its full range of discovery and oncology services, through its
discovery and pre-clinical platform. Carrick will progress multiple
programmes through hit-to-lead and lead optimisation with the goal of
delivering multiple development candidates.
Dr Werner Lanthaler, Chief Executive Officer of Evotec commented: "We are
very excited to be part of creating and co-owning a next generation leading
oncology company. Putting all Evotec's tools that support innovation and
capital efficiency at work will allow Carrick to very rapidly progress a
first-in-class oncology pipeline."
Chief Executive of Carrick Therapeutics, Dr Elaine Sullivan, said: "This is
a unique new venture in cancer treatment, backed by some of the highest
quality investors in the field. There is a significant unmet need in cancer
treatment, and targeting aggressive and resistant disease is an area where
we can make a real difference to patients' lives. Working with Evotec has
allowed us to build a pipeline with optimal speed and highest quality."
No further financial details are disclosed.
Evotec's financial guidance for 2016, also with regard to liquidity,
remains unchanged, despite the recent investment in Topas Therapeutics and
now Carrick Therapeutics.
ABOUT CARRICK THERAPEUTICS
Carrick Therapeutics is pioneering a portfolio of unique, first in class,
cancer treatments that target driver mechanisms of the most aggressive
forms of cancer, and which will be tailored to an individual patient's
tumour. The name Carrick means 'rock' in Irish to emphasise the strong
foundation of like-minded scientists, collaborators and investors, and the
vision to build a durable world-class company. Carrick has an ambitious
patient focussed vision to serve cancer patients around the world by the
introduction of ground breaking cancer therapies that will transform the
way cancer is treated.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide providing the highest
quality stand-alone and integrated drug discovery solutions, covering all
activities from target-to-clinic to meet the industry's need for innovation
and efficiency in drug discovery (EVT Execute). The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, diabetes and
complications of diabetes, pain and inflammation, oncology and infectious
diseases. On this basis, Evotec has built a broad and deep pipeline of more
than 70 partnered product opportunities at clinical, pre-clinical and
discovery stages (EVT Innovate). Evotec has established multiple long-term
discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and
development partnerships with e.g. Janssen Pharmaceuticals in the field of
Alzheimer's disease, with Sanofi in the field of diabetes and with Pfizer
in the field of tissue fibrosis. For additional information please go to
www.evotec.com.
FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgement of
Evotec as of the date of this press release. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.
Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, [email protected]
---------------------------------------------------------------------------
04.10.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
508341 04.10.2016
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Evotec AG ISIN: DE0005664809 können Sie bei EQS abrufen
Biotechnologie , 566480 , EVT , XETR:EVT